EDOCH Alternating With DHAP for New Diagnosed Younger MCL
Status:
Unknown status
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to:
1. determine the efficiency of EDOCH (etoposide,dexamethasone,doxorubicin, cyclophosphamide
and vincristine) alternating with DHAP (cisplatin, cytarabine and dexamethasone) regimen
combined with rituximab or not in young mantle cell lymphoma patients (ageā¤65 years);
2. determine the efficiency of rituximab and thalidomide plus prednisone as maintenance
regimens.